Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors
The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
- The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
- Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
- Maximizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123.
- With the successful realization of these requirements, Debio 0123 could become the first choice WEE1 inhibitor.